Literature DB >> 8071849

Angiotensin II receptor subtypes in bovine and human ventricular myocardium.

Y Nozawa1, A Haruno, N Oda, Y Yamasaki, N Matsuura, S Yamada, K Inabe, R Kimura, H Suzuki, T Hoshino.   

Abstract

Angiotensin II (AII) binding sites in bovine and human ventricular myocardium were characterized by a radioreceptor assay. The specific binding of [125I]AII to myocardial membranes appeared to be saturable, and it was of high affinity with apparent dissociation constants of 1.60 nM (bovine) and 1.09 nM (human). The Bmax values were 39.7 fmol/mg protein (bovine) and 6.07 fmol/mg protein (human). Both losartan (angiotensin type 1 receptor subtype selective antagonist) and PD123177 (the angiotensin type 2 receptor subtype selective antagonist) inhibited specific [125I]AII binding to bovine myocardium, and their Hill coefficients were less than unity. Nonlinear least-squares regression analysis has suggested the existence of two populations of [125I]AII binding sites that have high and low affinity for losartan or PD123177. The relative proportions of high- and low-affinity sites for losartan in bovine myocardium were 68% and 32%, and those for PD123177 were 33% and 67%, respectively. On the other hand, specific [125I]AII binding in human myocardium was inhibited by losartan with much lower affinity and also by PD123177 with higher affinity, compared with bovine myocardium. The Hill coefficients for both drugs were close to one. Dithiothreitol enhanced specific [125I]AII binding to bovine myocardium in the presence of losartan, but it reduced [125I]AII binding in the presence of PD123177. This agent markedly enhanced specific [125I]AII binding to human myocardium. Thus, it is possible that bovine myocardium has both angiotensin type 1 receptor and the angiotensin type 2 receptor subtypes of AII receptors whereas human myocardium has predominantly the angiotensin type 2 receptor subtype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8071849

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

Review 1.  Molecular biology of angiotensin receptors and their role in human cardiovascular disease.

Authors:  V Regitz-Zagrosek; M Neuss; J Holzmeister; C Warnecke; E Fleck
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

2.  Receptor occupancy in myocardium, adrenal cortex, and brain by TH-142177, a novel AT1 receptor antagonist in rats, in relation to its plasma concentration and hypotensive effect.

Authors:  Y Nozawa; H Miyake; S Yamada; R Kimura
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

3.  Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects.

Authors:  H Masaki; T Kurihara; A Yamaki; N Inomata; Y Nozawa; Y Mori; S Murasawa; K Kizima; K Maruyama; M Horiuchi; V J Dzau; H Takahashi; T Iwasaka; M Inada; H Matsubara
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

Review 4.  Subtype 2 and atypical angiotensin receptors in the human heart.

Authors:  V Regitz-Zagrosek; M Neuss; C Warnecke; J Holzmeister; A G Hildebrandt; E Fleck
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

5.  No evidence for a local renin-angiotensin system in liver mitochondria.

Authors:  Ronan Astin; Robert Bentham; Siamak Djafarzadeh; James A Horscroft; Rhoda E Kuc; Po Sing Leung; James R A Skipworth; Jose M Vicencio; Anthony P Davenport; Andrew J Murray; Jukka Takala; Stephan M Jakob; Hugh Montgomery; Gyorgy Szabadkai
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.